A case of pediatric B-Lymphoblastic leukemia presenting with a t(9;12)(p24;q11.2) involving JAK2 and concomitant MLL rearrangement with apparent insertion at 6q27

Carlos A Tirado1*, David Shabsovich2†, Matthew DeNicola1†, Dinesh Rao1, Lynn Yang1, Rolando Garcia3 and Nagesh Rao1

Abstract

Background: B-cell acute lymphoblastic leukemia (B-ALL) is the most common malignancy in pediatric patients and the leading cause of cancer-related death in children and young adults. Translocations of 9p24 involving JAK2 (9p24) and gain-of-function mutations of JAK2 with subsequent activation of the JAK2 kinase have been described in several hematological malignancies including B-ALL. However, rearrangements involving JAK2 are rare in B-ALL as only few cases have been described in the literature.

Findings: Herein, we present a case of pediatric B-ALL whose conventional cytogenetics revealed an abnormal karyotype with a reciprocal translocation involving 9p24 (JAK2) and 12p11.2. Fluorescence in situ hybridization (FISH) studies using the RP11-927H16 Spectrum Green JAK2 probe on previously G-banded metaphases confirmed the involvement of JAK2 in this rearrangement. Further FISH studies on the same previously G-banded metaphases using the LSI MLL probe helped to characterize an insertion of MLL into 6q27 as an additional abnormality in this karyotype. FISH studies performed on interphase nuclei also revealed an abnormal clone with MLL rearrangements in 23.6% of the nuclei examined as well as an abnormal clonal population with a deletion of the 5’IGH@ region in 88.3% of the nuclei examined.

Conclusions: Rearrangements of 9p24 can result in constitutive activation of JAK2, and have been observed in B-ALL. Rearrangements of the MLL gene have also been described extensively in B-ALL. However, rearrangements of MLL with a partner at 6q27 and in conjunction with a translocation involving JAK2 have not been previously described. This case pinpoints the importance of FISH and conventional cytogenetics to characterize complex rearrangements in which JAK2 and MLL are involved. The therapeutic targeting of JAK2 and MLL in cases like this may be prognostically beneficial.

Keywords: JAK2, MLL, FISH, B-ALL
Introduction
Abnormalities involving JAK2 (9p24) have been seen in B-ALL, but most often via point mutations involving the pseudokinase domain, R683 [1,2]. Rearrangements of 9p24, however, are rare, with only a small number of cases reported in the literature involving the following loci and partner genes: 22q11.2 (unknown gene), 12p13 (ETV6), 5p14.1 (SSBP2), 8p22 (PCMI), and 9p13.2 (PAX5) [1,3]. Activation of JAK2 occurs via gene fusions encoding chimeric proteins in which the kinase domain of JAK2 is fused to another cellular gene that provides a dimerization or oligomerization interface to the JAK2 kinase domain, leading to constitutive activation [1-5]. This case pinpoints the fact that JAK2 rearrangements may play an important role in the pathogenesis of lymphoblastic leukemias. To the best of our knowledge, this is one of the few cases with rearrangements of JAK2 with chromosome 12p11.2 as well as rearrangements of MLL involving chromosome 6q27, both with unknown partner genes.

Case presentation
A 13-year-old male presented with abdominal pain and fevers for three months. He was found to have leukocytosis (WBC 76.5x10^3/ul), anemia (Hgb 5.3 g/dL), and thrombocytopenia (platelet count 15.3x10^3/ul). Flow cytometry on peripheral blood revealed 94% blasts which expressed bright CD10, CD19, partial CD20, CD34, partial CD38, partial TdT, CD79a, and HLA-DR. A bone marrow biopsy showed a hypercellular marrow extensively involved (~95%) by sheets of lymphoblasts. These findings are consistent with a diagnosis of B-lymphoblastic leukemia. The patient was immediately started on induction chemotherapy with AALL0232 high-risk ALL chemotherapy protocol. A follow-up bone marrow biopsy on day 29 showed minimal residual disease (MRD). A normal karyotype was seen in all metaphase cells examined and loss of one copy of the 5' IGH@ was the only abnormality detected in 2.7% of the interphase nuclei studied. The patient subsequently was given treatment per clinical trial AALL0031 and achieved primary remission. Most recently, the patient received a successful allogeneic bone marrow transplant from a female donor.

Methods
Cytogenetics
Chromosome analysis was performed using standard cytogenetic techniques on bone marrow and peripheral blood, analyzing 20 metaphase cells. Karyotypes were prepared using Applied Imaging CytoVision software 2013 nomenclature [6].

FISH
Fluorescence in situ hybridization (FISH) was performed on interphase nuclei and previously G-banded metaphases using the RP11-927H16 Spectrum Green JAK2 probe (Empire Genomics, 700 Michigan Ave, suite 200, Buffalo, NY 14203) and the following probes: Vysis LSI MLL Dual Color Break Apart Probe, Vysis LSI ETV6 Dual Color Break Apart, Vysis LSI ETV6(TEL)/RUNX1(AML1) ES Dual Color Translocation Probe Set and Vysis LSI IGH Dual Color, Break Apart Rearrangement Probe from Abbott Molecular (Des Plaines, Illinois 60018).

Figure 1 Abnormal karyotype seen on G-banded chromosomes in the bone marrow: 46,XY,ins(6;11)(q27;q23q23),t(9;12), {p24;p11.2}[5]/46,XY[15].
Findings

Cytogenetics

Chromosome analysis of the bone marrow showed 5 of 20 cells with an *MLL* insertion on 6q27 as well as a balanced translocation between 9p24 and 12p11.2 (Figure 1). The same abnormalities were seen on a karyotype performed on peripheral blood, though at a lower frequency (1 of 20 cells).

In light of the FISH findings the karyotype of the bone marrow of this patient was described as: 46,XY,ins(6;11) (q27;q23q23),t(9;12),(p24;p11.2)[5]/46,XY[15].

FISH

FISH analysis using interphase nuclei showed *MLL* split signals in 23.6% (71/300) of the nuclei examined, suggestive of an *MLL* (11q23) gene rearrangement (Figure 2). However, FISH performed on previously G-banded metaphases also helped to identify two separate clonal populations with different *MLL* abnormalities: one with an *MLL* rearrangement mentioned above and one with an *MLL* insertion on chromosome 6q27 (Figure 3). Additionally, a deletion of the 5’ IGH@ region, corresponding to the variable segment of the IGH@ was seen in 88.3% (265/300) of the nuclei.
analyzed which may suggest a deletion of this region or an unbalanced rearrangement involving chromosome 14q32 (Figure 4).

FISH using the BAC RP11-927H16 probe (JAK2) showed a JAK2 signal on the normal copy of chromosome 9, a JAK2 signal on the short arm of chromosome 12, and a JAK2 signal on the derivative chromosome 9 (Figure 5). Because there were no abnormalities involving ETV6 (12p13), confirmed by using the Vysis LSI ETV6(TEL)/RUNX1 (AML1) ES Dual Color Translocation Probe Set on interphase cells (Figures 6) and the Vysis LSI ETV6 Dual Color Break Apart on metaphase cells (Figure 7), the breakpoints on chromosome 12 were defined as 12p11.2 (Figure 7).

The constellation of these results was described as: nuc ish(MLLx2)(5’MLL sep 3’MLLx1)[71/300]. nuc ish(ETV6,RUNX1)x2[300] .ish (5’ETV6,3’ETV6)x2 (5’ETV6 con 3’ETV6x2). nuc ish(3’IGH@x2,5’IGHx1) (3xIGH@con 5’IGH@x1) [265/300].

Discussion

The findings in this case - MLL rearrangements, abnormalities of the IGH@, 12p abnormalities, and rearrangements of 9p24 involving the JAK2 locus - have been previously described in B-ALL [1-3]. Abnormalities involving IGH@ have only been recently identified as a biologically and clinically relevant sub-group of B-ALL [7]. However deletions of the 5’ IGH@ region have not been well characterized in B-ALL in conjunction with JAK2 rearrangements and MLL abnormalities. JAK2 translocations have been reported in B-ALL, although at low frequencies. These B-ALL patients are most often male, present with hyperleukocytosis, respond poorly to chemotherapy, often relapse, and tend to have little to no cytogenetic abnormalities apart from those involving JAK2 [1]. This fact may suggest that JAK2 rearrangements play a driving role in the leukemogenesis of B-ALL.

JAK2 translocations induce dimerization or oligomerization of JAK2 without ligand binding, resulting in constitutive activation of JAK2-mediated tyrosine kinase pathways. It has been speculated that other cytogenetic abnormalities occurring in conjunction with JAK2 rearrangements in B-ALL may recruit other altered tyrosine kinase pathways that in turn, lead to an inferior clinical outcome. A correlation has also been observed between
CRLF2 (cytokine receptor-like factor 2) overexpression and JAK2 mutations, most likely because CRLF2 is a JAK-binding. Box 1 motif-containing cytokine receptor. Increased expression of CRLF2 independently has been correlated with a poor prognosis in B-ALL, and the synergistic effects of CRLF2 overexpression and JAK2 constitutive activation may play a major role in the leukemogenesis of the disease that can be prognostically considered and therapeutically targeted [8]. Similarly, even point mutations and rearrangements in the CRFL2 gene have been reported to activate aberrant JAK2 signaling [9].

While JAK2 translocations are not common in lymphoblastic leukemia, it is clear that newly developed small molecular JAK2 inhibitors such as TG101348 and TG10129 developed by TargetGen, Inc. show promising results in blocking the action of mutated JAK2 in myeloproliferative disorders [2,10]. There are at least 10 different JAK inhibitors undergoing various phases of clinical trials [11] including a group of TKIs used for both MPDs and non-MPDs, namely MK-0457 (previously VX-680), that has had JAK2 inhibitory action in MPD and reduced kinase activity in T315I-positive ALL and CML [2]. Lestaurtinib (CEP-701), used mainly for myeloid malignancies, has also been used in a clinical trial to treat children with B-ALL [11]. However, among neoplasias dependent on tyrosine kinases, treatment with
ATP-mimetic inhibitors has invariably resulted in the development of inhibitor resistance mutations [9]. A novel JAK2 inhibitor, NVP_BVB808 (BVB808), has been used experimentally in mice xenografted with human B-ALL to recover E864K, Y931C, and G935R mutations within the kinase domain of JAK2 that confer resistance to multiple JAK2 enzymatic inhibitors [9]. In addition, treatment with inhibitors of heat shock protein 90 (HSP90) has now been used experimentally to overcome all three resistance mutations and potentially kill cells dependent on JAK2. However, development of new therapies that target the abnormal JAK2 tyrosine kinase activity may benefit patients diagnosed with ALL presenting with JAK2 rearrangements [9].

Structural abnormalities involving the MLL gene (11q23) with various partner genes have been reported in ALL in ~6% of cases, but an MLL insertion at 6q27 has not been reported to the best of our knowledge [12]. Herein, conventional and molecular cytogenetic metaphase analysis solely revealed an insertion of MLL on chromosome 6q27 with an unknown fusion partner gene; however, further molecular cytogenetic studies on interphase nuclei unveiled a second clonal population of cells harboring an MLL rearrangement. Inversion of MLL may, however, have followed rearrangements with chromosome 6 (as opposed to preceding it). Limited sample material prevented further molecular characterization. Furthermore, MLL insertions have been reported to result in chimeric fusion genes and are usually associated with a poor prognosis [3,12].

In short, our case highlights the importance of using multiple tools, namely conventional cytogenetic and molecular genetic analysis, to elucidate complex rearrangements involving JAK2 and MLL genes. The detection and therapeutic targeting of MLL as well as JAK2 abnormalities in cases of ALL may be prognostically beneficial as they may represent a distinct subtype of acute lymphoblastic leukemia. To the best of our knowledge, this study is the first reported case of a pediatric B-ALL that shows a concurrent MLL gene rearrangement with a JAK2 translocation and deletion of the 5′ IGH region. This case sheds light on the potential significance of JAK2 and MLL as prognostic and therapeutic targets in lymphoblastic leukemias, and suggests further investigation to determine the benefits of the newly developed JAK2 inhibitors against translocations involving JAK2 in pediatric B-ALL.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
CAT led the entire writing of the manuscript. DS wrote the first draft, conducted a survey for relevant literature, and edited and revised future drafts. MDN contributed with the discussion and reviewed the manuscript. RG edited the manuscript and helped to organize the figures. DR contributed with the clinical history. LY conducted all the cytogenetics, FISH, and bench work and interpretation of the results. NR edited and revised the final draft. All authors read and approved the final manuscript.

Acknowledgement
To Dr. Christopher Kim for helping with the clinical history of this manuscript.

Author details
1Department of Pathology and Laboratory Medicine, David Geffen UCLA School of Medicine, Los Angeles, CA 90095, USA. 2Department of Microbiology, Immunology, and Molecular Genetics, UCLA, Los Angeles, CA 90095, USA. 3UT Southwestern Medical Center Department of Pathology, Dallas, Texas, USA.

Received: 7 November 2013 Accepted: 8 November 2013 Published: 25 November 2013

References
1. Tirado CA, et al.: Novel JAK2 rearrangement resulting from a t(9;12)(p24;q11.2) in B-acute lymphoblastic leukemia. Leuk Res. 2010, 34(12):1674–1676.
2. Ho K, et al.: JAK2 translocations in hematological malignancies: review of the literature. J Assoc Genet Technol 2010, 36(3):107–109.
3. Lactonique V, Boureau A, Vallee VD, et al.: A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 1997, 278:1309–1312.
4. Mullighan CG, et al.: JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci USA 2009, 106:9414–9418.
5. Smith CA, Fan G: The sage of JAK2 mutations and translocations in hematologic disorders: pathogenesis, diagnostic and therapeutic prospects, and revised World Health Organization diagnostic criteria for myeloproliferative neoplasms. Hum Pathol 2008, 39:795–810.
6. Shaffer LG, McGowan-Jordan J, Schmid MS: ISCN 2013: An International System of Human Cytogenetic Nomenclature. Unionville, CT, USA: S. Karger Publishers; Inc, 2013.
7. Moorman AV, Schwab C, Ensor HM, Russell LJ, Morrison H, Jones L, Matic D, Piet B, Rowe J, Tallman M, Golstone AH, Fielding AK, Harrison C: IGH@ translocations, CRLF2 deregulation, and microdeletions in adolescents and adults with acute lymphoblastic leukemia. J Clin Oncol 2012, 30:223100–223108.
8. Roll JD, Reutcher GW: CRLF2 And JAK2 in progenitor acute lymphoblastic leukemia: a novel association in oncogenesis. Cancer Res 2010, 70:7347–7352.
9. Wergert O, Laine AA, Bir L, Kopp N, Chapuy B, Van Bodegom D, Toms AV, Marubayashi S, Christie AL, McKeevon PRM, Bradner JE, Yoda A, Gaul C, Vangrevelinghe E, Romanet V, Murakami M, Tiedt R, Ebel N, Evert E, De Pover A, Reigner CH, Erdmann D, Hoffmann F, Eck M, Sallan SE, Levine RL, Kung AL, Baffet F, Radimerski T, Weinstock DM: Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSPP90 inhibition. J Exp Med 2012, 209(2):259–273.
10. Hood J, Doukas J, Martin M, Noronha G, Jamieson C, Soll R: TG101348, a potent, highly selective JAK2 inhibitor, inhibits colony formation in stem cells from polycythemia vera patients and prevents JAKC617F-mediated splenomegaly and death in a mouse model. J Clin Oncol 2007, 25:7031.
11. Muhammad F, Nikhil M, Byung L, Delong L: Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application, Biomarker Res 2013, 1:5.
12. Tirado CA, Lager J, Rosoff PM, et al.: A case of infantile acute lymphoblastic leukemia presenting with rearrangement of MLL at 11q23 and apparent insertion or translocation at 10p12. Cancer Genet Cytopathol 2004, 154:57–59.

Cite this article as: Tirado et al.: A case of pediatric B-Lymphoblastic leukemia presenting with a t(9;12)(p24;q11.2) involving JAK2 and concomitant MLL rearrangement with apparent insertion at 6q27. Biomarker Research 2013 1:31.